GPs advised on flu vaccines for 2018/19 as NHS promises extra funds
GPs, pharmacists and CCGs have been reminded of official advice on the most effective vaccines for patients in at-risk groups and over-65s, as NHS England pledged extra funding for the 2018/19 flu season.
(Reuters Health) - Infants are much less likely to get influenza or whooping cough when their mothers were vaccinated against these infections during pregnancy, and a new study suggests this doesn ’t pose a safety risk for babies.
Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection, Published online: 21 February 2018; doi:10.1038/s41385-018-0004-9Vaccine-induced antigen-specific regulatory T cells attenuate the antiviral immunity against acute influenza virus infection
A flu shot is recommended for every person older than 6 months in the United States, even though the CDC reported on Thursday that this year's vaccine is only 25 percent effective against H3N2 influenza, the cause of most illness so far this season.
A group of US senators last week unveiled a proposal to invest $1 billion in research over the next 5 years to create a universal flu vaccine that would provide lifetime protection against a range of influenza strains.
Maternal influenza and Tdap vaccinations during pregnancy do not increase the risk for hospitalization or death among infants agexd 0 to 6 months, a new study showed.Medscape Medical News
(InDevR, Inc.) InDevR has expanded its VaxArray ® product portfolio with a new reagent kit to address the 'need for speed' in combating flu viruses with pandemic potential. The VaxArray Influenza Pandemic Hemagglutinin potency test kit is now available for flu vaccines containing H5, H7, and H9 flu subtypes, which includes new H7 vaccines against the deadly avian H7N9 virus. This new potency assay enables rapid determination of immunogenic hemagglutinin in low-dose and adjuvanted flu vaccines.
Susan L. Baldwin, Fan-Chi Hsu, Neal Van Hoeven, Emily Gage, Brian Granger, Jeffrey A. Guderian, Sasha E. Larsen, Erica C. Lorenzo, Laura Haynes, Steven G. Reed, Rhea N. Coler
Condition: Influenza Interventions: Biological: Immunose™ FLU 1%; Biological: Immunose™ FLU 2%, 200 μl; Biological: Immunose™ FLU 2%, 300 μl; Biological: Influenza antigen; Drug: Placebo; Biological: i.m comparator Sponsor: Eurocine Vaccines AB Recruiting
Conditions: Influenza, Human; Pregnancy; Birth Defect Interventions: Biological: Flucelvax Trivalent Influenza Vaccine; Biological: Flucelvax Quadrivalent Influenza Vaccine Sponsor: Seqirus Recruiting